Fingerhut out as Cleveland Clinic Innovations ED

The executive director of Cleveland Clinic Innovations is out after the FBI told the hospital system that he made financial transactions that violated internal policies.

Gary Fingerhut, who became executive director in 2013, allegedly engaged in financial transactions with one of the clinic's spin-off companies. The FBI is not investigating Cleveland Clinic and would not confirm or deny whether the agency is formally investigating Fingerhut. has left the Cleveland Clinic after the FBI told the hospital system that he made financial transactions that violated the hospital system's internal policies.

The chairman of Cleveland Clinic Innovations, Thomas Graham, MD, will serve as executive director of the unit while the clinic searches for Fingerhut's replacement.

Fingerhut joined Innovations as its general manager for IT commercialization four years ago. He was chosen to replace Chris Coburn as executive director in 2013.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.